Compare HIMS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMS | BLCO |
|---|---|---|
| Founded | 2017 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 2019 | 2022 |
| Metric | HIMS | BLCO |
|---|---|---|
| Price | $23.73 | $16.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $30.46 | $18.45 |
| AVG Volume (30 Days) | ★ 21.1M | 475.0K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,347,637,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $19.82 | $8.65 |
| Revenue Next Year | $19.23 | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 59.00 | 6.47 |
| 52 Week Low | $13.74 | $10.99 |
| 52 Week High | $70.43 | $18.92 |
| Indicator | HIMS | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 49.43 |
| Support Level | $18.62 | $14.39 |
| Resistance Level | $31.12 | $16.41 |
| Average True Range (ATR) | 1.64 | 0.39 |
| MACD | -0.61 | 0.03 |
| Stochastic Oscillator | 24.79 | 63.76 |
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.